Keymed Biosciences reports efficacy and safety data from phase III trial of stapokibart to treat moderate─to─severe ...
Keymed Biosciences Inc, announced the long-term efficacy and safety data of a phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral presentation at the European Academy …